title: Pharmaceutical approval update.
abstract: Apremilast (Otezla) for active psoriatic arthritis, omalizumab (Xolair) for chronic idiopathic urticaria, and grass pollen allergen extract (Oralair) for grass pollen-induced allergic rhinitis with or without conjunctivitis.
authors: Marvin M
authors: MM
authors: Goldenberg